MorphoSys

Emergent BioSolutions, MorphoSys ink agreement for ES414

Friday, August 22, 2014

Emergent BioSolutions, a Rockville, Md.-based global specialty biopharmaceutical company, and MorphoSys, a Germany-based provider of therapeutic antibodies, have inked an agreement for the joint development and commercialization of Emergent’s preclinical bi-specific antibody, ES414, targeting prostate cancer. Emergent will receive an upfront payment of $20 million and milestone payments of up to $163 million.

[Read More]

MorphoSys, Celgene to jointly develop cancer program

Tuesday, July 2, 2013

Global biopharma companies MorphoSys and Celgene have agreed to jointly develop MOR202 globally and co-promote it in Europe. MOR202 is a fully human monoclonal antibody targeting CD38 to treat patients with multiple myeloma and certain leukemias. It currently is being evaluated in a phase I/IIa trial in patients with relapsed/refractory myeloma. The companies will collaborate on the development of MOR202 in multiple myeloma and other indications and share costs.

[Read More]